Sonablate®-500:: transrectal high-intensity focused ultrasound for the treatment of prostate cancer
Sonablate®-500:: transrectal high-intensity focused ultrasound for the treatment of prostate cancer
复制标题
DOI：
10.1586/17434440.3.6.717
复制
发表时间：
2006-11-01
影响因子：
3.1
通讯作者：
Emberton, Mark
中科院分区：
文献类型：
--
作者：
Illing, Rowland;Emberton, Mark
前列腺癌（PCa）是男性最常见的癌症，也是英国恶性肿瘤死亡的第二大原因。被诊断患有前列腺癌的男性人数正在增加，部分原因是男性有下尿路症状时愿意去看家庭医生，医生也愿意进行检查。随着被诊断患有前列腺癌的男性人口变得更年轻，更了解情况，因此对标准疗法的微创替代疗法的需求变得更大。Sonablate（R）-500是仅有的两种可用于治疗PCa的高强度聚焦超声（HIFU）设备之一。HIFU是一种有吸引力的治疗选择，因为它是唯一既不涉及前列腺直接器械也不涉及电离辐射的治疗形式。本文描述了Sonablate（R）-500系统硬件和软件的独特功能，以及该设备在当前标准治疗背景下的结局数据。最后，展望未来，试图概述这项技术的发展方向，以及如何在模式转变的方式，PCa被认为可能使HIFU更相关。
Prostate cancer (PCa) is the most common cancer in men and the second leading cause of death from malignancy in the UK. The number of men diagnosed with PCa is increasing, due in part to an increased willingness of men to visit their family doctors with lower urinary tract symptoms, and also a willingness of physicians to test for it. As the demographic of men diagnosed with PCa becomes younger and better informed, so the demand for a less-invasive alternative to standard therapies becomes greater. The Sonablate(R)-500 is one of only two high-intensity focused ultrasound (HIFU) devices commercially available to treat PCa. HIFU is an attractive treatment option as it is the only form of therapy that neither involves direct instrumentation of the prostate nor ionizing radiation. This article describes the unique features of both the Sonablate(R)-500 system hardware and software, and the outcome data from this device in the context of current standard therapies. Finally, a view into the future attempts to outline where this technology is heading and how a paradigm shift in the way that PCa is considered may make HIFU even more relevant.